The expression of programmed cell death protein 1 (PD-1), by FCM, has been essential to establishing the initiation of therapy with blocking mAbs of PD-1 or PD-L1, and thus, improve the response of the immune system against tumour cells and improve the quality of life of patients [79,80]. The gene discussed is PDCD1; the disease is neoplasm.